"Global Cancer Immunotherapy Market Overview:
Global Cancer Immunotherapy Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Cancer Immunotherapy Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Cancer Immunotherapy involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Cancer Immunotherapy Market:
The Cancer Immunotherapy Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Cancer Immunotherapy Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Cancer Immunotherapy Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Cancer Immunotherapy market has been segmented into:
Immune checkpoint inhibitors
Vaccines
Adoptive Cell Therapies
Immune System Modulators
Monoclonal antibodies
Oncolytic Virus Therapy
By Application, Cancer Immunotherapy market has been segmented into:
Subcutaneous
Oral
Intramuscular
Intravenous
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Cancer Immunotherapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Cancer Immunotherapy market.
Top Key Players Covered in Cancer Immunotherapy market are:
Gilead Sciences
Inc.
Johnson & Johnson
Actym Therapeutics
Inc.
Bristol-Myers Squibb Company
Pfizer Inc
Novartis AG
Merck & Co.
Inc.
Fate Therapeutics.
AstraZeneca
Amgen Inc.
GSK plc.
Acumen Pharmaceuticals
Inc
Arcus Biosciences
Inc.
BioNTech SE
Cellectis
immunitybio inc
Autolus Therapeutics
ADC Therapeutics SA.
Gritstone bio
Incyte
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Cancer Immunotherapy Market by Type
4.1 Cancer Immunotherapy Market Snapshot and Growth Engine
4.2 Cancer Immunotherapy Market Overview
4.3 Immune checkpoint inhibitors
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Immune checkpoint inhibitors: Geographic Segmentation Analysis
4.4 Vaccines
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Vaccines: Geographic Segmentation Analysis
4.5 Adoptive Cell Therapies
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Adoptive Cell Therapies: Geographic Segmentation Analysis
4.6 Immune System Modulators
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Immune System Modulators: Geographic Segmentation Analysis
4.7 Monoclonal antibodies
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Monoclonal antibodies: Geographic Segmentation Analysis
4.8 Oncolytic Virus Therapy
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Oncolytic Virus Therapy: Geographic Segmentation Analysis
Chapter 5: Cancer Immunotherapy Market by Application
5.1 Cancer Immunotherapy Market Snapshot and Growth Engine
5.2 Cancer Immunotherapy Market Overview
5.3 Subcutaneous
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Subcutaneous: Geographic Segmentation Analysis
5.4 Oral
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Oral: Geographic Segmentation Analysis
5.5 Intramuscular
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Intramuscular: Geographic Segmentation Analysis
5.6 Intravenous
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Intravenous: Geographic Segmentation Analysis
5.7 Other
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Other: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Cancer Immunotherapy Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 GILEAD SCIENCES
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 INC.
6.4 JOHNSON & JOHNSON
6.5 ACTYM THERAPEUTICS
6.6 INC.
6.7 BRISTOL-MYERS SQUIBB COMPANY
6.8 PFIZER INC
6.9 NOVARTIS AG
6.10 MERCK & CO.
6.11 INC.
6.12 FATE THERAPEUTICS.
6.13 ASTRAZENECA
6.14 AMGEN INC.
6.15 GSK PLC.
6.16 ACUMEN PHARMACEUTICALS
6.17 INC
6.18 ARCUS BIOSCIENCES
6.19 INC.
6.20 BIONTECH SE
6.21 CELLECTIS
6.22 IMMUNITYBIO INC
6.23 AUTOLUS THERAPEUTICS
6.24 ADC THERAPEUTICS SA.
6.25 GRITSTONE BIO
6.26 INCYTE
Chapter 7: Global Cancer Immunotherapy Market By Region
7.1 Overview
7.2. North America Cancer Immunotherapy Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Immune checkpoint inhibitors
7.2.4.2 Vaccines
7.2.4.3 Adoptive Cell Therapies
7.2.4.4 Immune System Modulators
7.2.4.5 Monoclonal antibodies
7.2.4.6 Oncolytic Virus Therapy
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Subcutaneous
7.2.5.2 Oral
7.2.5.3 Intramuscular
7.2.5.4 Intravenous
7.2.5.5 Other
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Cancer Immunotherapy Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Immune checkpoint inhibitors
7.3.4.2 Vaccines
7.3.4.3 Adoptive Cell Therapies
7.3.4.4 Immune System Modulators
7.3.4.5 Monoclonal antibodies
7.3.4.6 Oncolytic Virus Therapy
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Subcutaneous
7.3.5.2 Oral
7.3.5.3 Intramuscular
7.3.5.4 Intravenous
7.3.5.5 Other
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Cancer Immunotherapy Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Immune checkpoint inhibitors
7.4.4.2 Vaccines
7.4.4.3 Adoptive Cell Therapies
7.4.4.4 Immune System Modulators
7.4.4.5 Monoclonal antibodies
7.4.4.6 Oncolytic Virus Therapy
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Subcutaneous
7.4.5.2 Oral
7.4.5.3 Intramuscular
7.4.5.4 Intravenous
7.4.5.5 Other
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Cancer Immunotherapy Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Immune checkpoint inhibitors
7.5.4.2 Vaccines
7.5.4.3 Adoptive Cell Therapies
7.5.4.4 Immune System Modulators
7.5.4.5 Monoclonal antibodies
7.5.4.6 Oncolytic Virus Therapy
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Subcutaneous
7.5.5.2 Oral
7.5.5.3 Intramuscular
7.5.5.4 Intravenous
7.5.5.5 Other
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Cancer Immunotherapy Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Immune checkpoint inhibitors
7.6.4.2 Vaccines
7.6.4.3 Adoptive Cell Therapies
7.6.4.4 Immune System Modulators
7.6.4.5 Monoclonal antibodies
7.6.4.6 Oncolytic Virus Therapy
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Subcutaneous
7.6.5.2 Oral
7.6.5.3 Intramuscular
7.6.5.4 Intravenous
7.6.5.5 Other
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Cancer Immunotherapy Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Immune checkpoint inhibitors
7.7.4.2 Vaccines
7.7.4.3 Adoptive Cell Therapies
7.7.4.4 Immune System Modulators
7.7.4.5 Monoclonal antibodies
7.7.4.6 Oncolytic Virus Therapy
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Subcutaneous
7.7.5.2 Oral
7.7.5.3 Intramuscular
7.7.5.4 Intravenous
7.7.5.5 Other
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Cancer Immunotherapy Scope:
|
Report Data
|
Cancer Immunotherapy Market
|
|
Cancer Immunotherapy Market Size in 2025
|
USD XX million
|
|
Cancer Immunotherapy CAGR 2025 - 2032
|
XX%
|
|
Cancer Immunotherapy Base Year
|
2024
|
|
Cancer Immunotherapy Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Gilead Sciences, Inc., Johnson & Johnson, Actym Therapeutics, Inc., Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Merck & Co., Inc., Fate Therapeutics., AstraZeneca, Amgen Inc., GSK plc., Acumen Pharmaceuticals, Inc, Arcus Biosciences, Inc., BioNTech SE, Cellectis, immunitybio inc, Autolus Therapeutics, ADC Therapeutics SA., Gritstone bio, Incyte.
|
|
Key Segments
|
By Type
Immune checkpoint inhibitors
Vaccines
Adoptive Cell Therapies
Immune System Modulators
Monoclonal antibodies
Oncolytic Virus Therapy
By Applications
Subcutaneous
Oral
Intramuscular
Intravenous
Other
|
